文摘
摘要目的:检查实际的有效性ubrogepant急性治疗偏头痛的病人转向ubrogepant之前由于缺少有效性的急性治疗。
背景:的安全性和有效性ubrogepant第三阶段实现试验证实了;然而,ubrogepant在实际设置的有效性还有待充分的特点。
设计/方法:宇宙(Ubrogepant用户的经验:患者Ubrogepant,特点和结果)的研究是一个观察横断面研究我们成人偏头痛伙伴应用程序的用户谁自述使用Ubrogepant≥4偏头痛之前,包括≥1剂量前14天。合格的参与者完成了29-question调查评估病人的特点,治疗模式,结果,与ubrogepant和满意度。
结果:302名受访者,87.4% (n = 264)转向ubrogepant由于之前缺乏疗效的治疗。对于这个群,平均年龄42岁,89%是女性,35.6%慢性偏头痛,55.9%之前尝试≥3曲坦类。绝大多数报道被满意ubrogepant实现缓解疼痛在2小时(76.1%),4小时(83.3%),和24小时(78.4%)post-dose。大部分报道满意度清晰思考的能力(85.2%)和ubrogepant治疗后恢复正常功能(84.8%)。绝大多数(91.7%)称他们可能继续ubrogepant使用。之前的分析和并发急性药物显示减少阿片类药物的使用(−28%),巴比妥酸盐(−25%)、麦角(−15%)、药物(−55%),非甾体类抗炎药(−38%),和其他急性药物类(−37%)。
结论:在患者自我报告缺乏有效性的原因治疗失败之前,ubrogepant使用高满意度实现缓解疼痛,清晰思考的能力,和恢复正常功能。大多数人表示,他们可能会继续使用。Ubrogepant也与减少阿片类药物和巴比妥酸盐使用,为用户显示更多的临床效益。
披露:Anand r . Shewale已收到AbbVie的个人作为一个雇员补偿。Anand r . Shewale收到AbbVie股票或所有权权益。Poh博士已经收到Healint的个人作为一个雇员补偿。Poh博士获得了股票或PathoVax的所有者权益,LLC。里德博士的机构已收到个人薪酬在10000 - 49999美元的范围为礼来公司担任顾问。里德博士的机构收到爱力根的研究支持。里德博士的机构收到Reddy博士的实验室研究支持/ Promius。里德博士已经收到了研究的机构支持减轻灯。里德博士non-compensated关系作为研究分析师河畔与国家头痛基金会相关的利益或活动。刘太太已经收到个人赔偿作为《创世纪》研究的一个员工。Cadiou先生已经收到Healint的个人作为一个雇员补偿。 Ms. Burslem has received personal compensation for serving as an employee of AbbVie. Ms. Burslem has received stock or an ownership interest from AbbVie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in CtrlM Health. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NINDS. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from Veterans Administration. The institution of Dr. Lipton has received research support from NIH. Dr. Lipton has received publishing royalties from a publication relating to health care.
